A novel chemogenomics analysis of G protein-coupled receptors (GPCRs) and their ligands: A potential strategy for receptor de-orphanization

BMC Bioinformatics

Volumn 11, Issue , 2010, Pages

  van der Horst, Eelke ^a   Peironcely, Julio E ^a   IJzerman, Adriaan P ^a   Beukers, Margot W ^a   Lane, Jonathan R ^a   van Vlijmen, Herman W T ^a   Emmerich, Michael T M ^b   Okuno, Yasushi ^c   Bender, Andreas ^a,d  

^a LEIDEN UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c KYOTO UNIVERSITY   (Japan)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE RECEPTOR; CANNABINOID RECEPTORS; G PROTEIN COUPLED RECEPTORS; LIGAND BINDING PROPERTIES; LIGAND INTERACTIONS; PHYLOGENETIC CLASSIFICATIONS; SEROTONIN RECEPTORS; THERAPEUTIC VALUES;

BINDING ENERGY; PROTEINS;

LIGANDS;

G PROTEIN COUPLED RECEPTOR; LIGAND;

ARTICLE; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; CLASSIFICATION; DRUG DESIGN; GENOMICS; METHODOLOGY; PHYLOGENY;

BINDING SITES; DRUG DESIGN; GENOMICS; LIGANDS; MODELS, MOLECULAR; PHYLOGENY; RECEPTORS, G-PROTEIN-COUPLED;

EID: 77953235731     PISSN: None     EISSN: 14712105     Source Type: Journal    
DOI: 10.1186/1471-2105-11-316     Document Type: Article

References (59)

1. Fredriksson R, Lagerstrom MC, Lundin L-G, Schioth HB. The G-Protein-Coupled Receptors in the Human Genome Form Five Main Families. Phylogenetic Analysis, Paralogon Groups, and Fingerprints. Molecular Pharmacology 2003, 63(6):1256-1272. 10.1124/mol.63.6.1256, 12761335.
2. Jacoby E, Bouhelal R, Gerspacher M, Seuwen K. The 7 TM G-Protein-Coupled Receptor Target Family. Chem Med Chem 2006, 1(8):760-782.
3. Jaakola V-P, Griffith MT, Hanson MA, Cherezov V, Chien EYT, Lane JR, IJzerman AP, Stevens RC. The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist. Science 2008, 1164772.
4. Ballesteros J, Palczewski K. G protein-coupled receptor drug discovery: Implications from the crystal structure of rhodopsin. Curr Opin Drug Discovery Dev 2001, 4(5):561-574.
5. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SGF, Thian FS, Kobilka TS, Choi H-J, Kuhn P, Weis WI, Kobilka BK, et al. High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein Coupled Receptor. Science 2007, 318(5854):1258-1265. 10.1126/science.1150577, 2583103, 17962520.
6. Warne T, Serrano-Vega MJ, Baker JG, Moukhametzianov R, Edwards PC, Henderson R, Leslie AGW, Tate CG, Schertler GFX. Structure of a β1-adrenergic G-protein-coupled receptor. Nature 2008, 454(7203):486-491. 10.1038/nature07101, 18594507.
7. Klabunde T, Hessler G. Drug Design Strategies for Targeting G-Protein-Coupled Receptors. Chem Bio Chem 2002, 3(10):928-944.
8. Balakin KV, Tkachenko SE, Lang SA, Okun I, Ivashchenko AA, Savchuk NP. Property-Based Design of GPCR-Targeted Library. J Chem Inf Comput Sci 2002, 42(6):1332-1342.
9. Chang LCW, Spanjersberg RF, von Frijtag Drabbe-Künzel JK, Mulder-Krieger T, van den Hout G, Beukers MW, Brussee J, IJzerman AP. 2,4,6-Trisubstituted Pyrimidines as a New Class of Selective Adenosine A1 Receptor Antagonists. J Med Chem 2004, 47(26):6529-6540. 10.1021/jm049448r, 15588088.
10. Bywater R. Privileged Structures in GPCRs. GPCRs: From Deorphanization to Lead Structure Identification 2007, 75-92. Springer-Verlag, Bourne H, Horuk R, Kuhnke J, Michel H.
11. Doddareddy MR, Westen G, Horst E, Peironcely JE, Corthals F, IJzerman AP, Emmerich M, Jenkins JL, Bender A. Chemogenomics: Looking at biology through the lens of chemistry. Statistical Analysis and Data Mining 2009, 2(3):149-160.
12. Bender A, Young DW, Jenkins JL, Serrano M, Mikhailov D, Clemons PA, Davies JW. Chemogenomic data analysis: Prediction of small-molecule targets and the advent of biological fingerprints. Comb Chem High Throughput Screening 2007, 10(8):719-731.
13. Klabunde T. Chemogenomic approaches to drug discovery: similar receptors bind similar ligands. Br J Pharmacol 2007, 152(1):5-7. 10.1038/sj.bjp.0707308, 1978276, 17533415.
14. Kolakowski LFJ. GCRDb: a G-protein-coupled receptor database. Recept Channels 1994, 2:1-7.
15. Surgand J-S, Rodrigo J, Kellenberger E, Rognan D. A chemogenomic analysis of the transmembrane binding cavity of human G-protein-coupled receptors. Proteins: Struct, Funct, Bioinf 2006, 62(2):509-538.
16. Rasmussen SGF, Choi H-J, Rosenbaum DM, Kobilka TS, Thian FS, Edwards PC, Burghammer M, Ratnala VRP, Sanishvili R, Fischetti RF, et al. Crystal structure of the human β2 adrenergic G-protein-coupled receptor. Nature 2007, 450(7168):383-387. 10.1038/nature06325, 17952055.
17. Gloriam DE, Foord SM, Blaney FE, Garland SL. Definition of the G Protein-Coupled Receptor Transmembrane Bundle Binding Pocket and Calculation of Receptor Similarities for Drug Design. J Med Chem 2009, 52(14):4429-4442. 10.1021/jm900319e, 19537715.
18. Bender A, Jenkins JL, Glick M, Deng Z, Nettles JH, Davies JW. "Bayes Affinity Fingerprints" Improve Retrieval Rates in Virtual Screening and Define Orthogonal Bioactivity Space: When Are Multitarget Drugs a Feasible Concept?. J Chem Inf Model 2006, 46(6):2445-2456. 10.1021/ci600197y, 17125186.
19. Bender A, Scheiber J, Glick M, Davies JW, Azzaoui K, Hamon J, Urban L, Whitebread S, Jenkins JL. Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off-Target Effects from Chemical Structure. ChemMedChem 2007, 2(6):861-873. 10.1002/cmdc.200700026, 17477341.
20. Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, Shoichet BK. Relating protein pharmacology by ligand chemistry. Nat Biotech 2007, 25(2):197-206.
21. van der Horst E, Okuno Y, Bender A, IJzerman AP. Substructure Mining of GPCR Ligands Reveals Activity-Class Specific Functional Groups in an Unbiased Manner. J Chem Inf Model 2009, 49(2):348-360. 10.1021/ci8003896, 19434836.
22. Borgelt C, Berthold MR. Mining Molecular Fragments: Finding Relevant Substructures of Molecules. Proceedings of the 2002 IEEE International Conference on Data Mining: 2002 2002, 51-58. IEEE Computer Society.
23. Nijssen S, Kok JN. A quickstart in frequent structure mining can make a difference. Proceedings of the tenth ACM SIGKDD international conference on Knowledge discovery and data mining: 2004 2004, 647-652. ACM Press, New York, USA.
24. Foord SM, Bonner TI, Neubig RR, Rosser EM, Pin J-P, Davenport AP, Spedding M, Harmar AJ. International Union of Pharmacology. XLVI. G Protein-Coupled Receptor List. Pharmacol Rev 2005, 57(2):279-288. 10.1124/pr.57.2.5, 15914470.
25. Horn F, Bettler E, Oliveira L, Campagne F, Cohen FE, Vriend G. GPCRDB information system for G protein-coupled receptors. Nucl Acids Res 2003, 31(1):294-297. 10.1093/nar/gkg103, 165550, 12520006.
26. Baker JG. The selectivity of β-adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptors. Br J Pharmacol 2005, 144(3):317-322. 10.1038/sj.bjp.0706048, 1576008, 15655528.
27. Van Zwieten PA, Doods HN. Muscarinic receptors and drugs in cardiovascular medicine. Cardiovascular Drugs and Therapy 1995, 9(1):159-167. 10.1007/BF00877757, 7786837.
28. Voigtländer U, Jöhren K, Mohr M, Raasch A, Tränkle C, Buller S, Ellis J, Höltje H-D, Mohr K. Allosteric site on muscarinic acetylcholine receptors: identification of two amino acids in the muscarinic M2 receptor that account entirely for the M2/M5 subtype selectivities of some structurally diverse allosteric ligands in N-methylscopolamine-occupied receptors. Molecular Pharmacology 2003, 64(1):21-31. 10.1124/mol.64.1.21, 12815157.
29. Okuno Y, Tamon A, Yabuuchi H, Niijima S, Minowa Y, Tonomura K, Kunimoto R, Feng C. GLIDA: GPCR ligand database for chemical genomics drug discovery database and tools update. Nucl Acids Res 2008, 36(suppl_1):D907-912. 2238933, 17986454.
30. Paolini GV, Shapland RHB, van Hoorn WP, Mason JS, Hopkins AL. Global mapping of pharmacological space. Nat Biotech 2006, 24(7):805-815.
31. Cuisiat S, Bourdiol N, Lacharme V, Newman-Tancredi A, Colpaert F, Vacher B. Towards a New Generation of Potential Antipsychotic Agents Combining D2 and 5-HT1A Receptor Activities. J Med Chem 2007, 50(4):865-876. 10.1021/jm061180b, 17300168.
32. Lawrence AJ. Optimisation of anti-psychotic therapeutics: a balancing act?. Br J Pharmacol 2007, 151(2):161-162. 10.1038/sj.bjp.0707164, 2013954, 17375084.
33. Bondensgaard K, Ankersen M, Thogersen H, Hansen BS, Wulff BS, Bywater RP. Recognition of Privileged Structures by G-Protein Coupled Receptors. J Med Chem 2004, 47(4):888-899. 10.1021/jm0309452, 14761190.
34. Schnur DM, Hermsmeier MA, Tebben AJ. Are Target-Family-Privileged Substructures Truly Privileged?. J Med Chem 2006, 49(6):2000-2009. 10.1021/jm0502900, 16539387.
35. Abramovitz M, Adam M, Boie Y, Carrière M-C, Denis D, Godbout C, Lamontagne S, Rochette C, Sawyer N, Tremblay NM, et al. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta, Mol Cell Biol Lipids 2000, 1483(2):285-293.
36. Pettipher R, Hansel TT, Armer R. Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat Rev Drug Discov 2007, 6(4):313-325. 10.1038/nrd2266, 17396136.
37. Wang S, Gustafson E, Pang L, Qiao X, Behan J, Maguire M, Bayne M, Laz T. A Novel Hepatointestinal Leukotriene B4 Receptor. Cloning and Functional Characterization. J Biol Chem 2000, 275(52):40686-40694. 10.1074/jbc.M004512200, 11006272.
38. Yokomizo T, Izumi T, Chang K, Takuwa Y, Shimizu T. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 1997, 387(6633):620-624. 10.1038/42506, 9177352.
39. Le Crom S, Kapsimali M, Barôme P-O, Vernier P. Dopamine receptors for every species: Gene duplications and functional diversification in Craniates. Journal of Structural and Functional Genomics 2003, 3(1):161-176. 10.1023/A:1022686622752, 12836695.
40. Zhang J, Xiong B, Zhen X, Zhang A. Dopamine D1 receptor ligands: where are we now and where are we going. Med Res Rev 2009, 29(2):272-294. 10.1002/med.20130, 18642350.
41. Roth BL, Sheffler D, Potkin SG. Atypical antipsychotic drug actions: unitary or multiple mechanisms for 'atypicality'?. Clinical Neuroscience Research 2003, 3(1-2):108-117.
42. Coward DM. General pharmacology of clozapine. The British Journal of Psychiatry Supplement 1992, (17):5-11.
43. Zakon HH. Convergent Evolution on the Molecular Level. Brain, Behavior and Evolution 2002, 59(5-6):250-261. 10.1159/000063562, 12207082.
44. Mestres J, Gregori-Puigjane E, Valverde S, Sole RV. Data completeness--the Achilles heel of drug-target networks. Nat Biotech 2008, 26(9):983-984.
45. Bemis GW, Murcko MA. The Properties of Known Drugs. 1. Molecular Frameworks. J Med Chem 1996, 39(15):2887-2893. 10.1021/jm9602928, 8709122.
46. van der Horst E, IJzerman AP. Computational Approaches to Fragment and Substructure Discovery and Evaluation. Fragment-Based Drug Discovery: A Practical Approach 2008, West Sussex, U.K.: John Wiley & Sons, Ltd, Zartler ER, Shapiro J, Chichester M.
47. Bernasconi P, Min C, Galasinski S, Popa-Burke I, Bobasheva A, Coudurier L, Birkos S, Hallam R, Janzen WP. A Chemogenomic Analysis of the Human Proteome: Application to Enzyme Families. J Biomol Screen 2007, 12(7):972-982. 10.1177/1087057107306759, 17942790.
48. ChEMBL. , http://www.ebi.ac.uk/chembl/
49. Roth BL, Lopez E, Beischel S, Westkaemper RB, Evans JM. Screening the receptorome to discover the molecular targets for plant-derived psychoactive compounds: a novel approach for CNS drug discovery. Pharmacol Ther 2004, 102(2):99-110. 10.1016/j.pharmthera.2004.03.004, 15163592.
50. The UniProt Consortium The Universal Protein Resource (UniProt). Nucl Acids Res 2008, 36(suppl_1):D190-195. 2238893, 18045787, The UniProt Consortium.
51. Wheeler DL, Barrett T, Benson DA, Bryant SH, Canese K, Chetvernin V, Church DM, DiCuccio M, Edgar R, Federhen S, et al. Database resources of the National Center for Biotechnology Information. Nucl Acids Res 2008, (36 Database):D13-D21. 2238880, 18045790.
52. Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, Chang Z, Woolsey J. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucl Acids Res 2006, 34(suppl_1):D668-672. 10.1093/nar/gkj067, 1347430, 16381955.
53. GPCRDB. , http://www.gpcr.org/7tm/
54. GASTON. , http://www.liacs.nl/~snijssen/gaston/
55. Wörlein M, Meinl T, Fischer I, Philippsen M. A Quantitative Comparison of the Subgraph Miners MoFa, gSpan, FFSM, and Gaston. Knowledge Discovery in Databases: PKDD 2005 2005, 392-403.
56. Agrawal R, Srikant R. Fast Algorithms for Mining Association Rules in Large Databases. Proceedings of the 20th International Conference on Very Large Data Bases: September 12 - 15 1994 1994, 487-499. Morgan Kaufmann Publishers, San Francisco, CA.
57. Felsenstein J. PHYLIP (Phylogeny Inference Package) version 3.6. Distributed by the author. Department of Genome Sciences, University of Washington, Seattle. 2005,
58. Tamura K, Dudley J, Nei M, Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) Software Version 4.0. Mol Biol Evol 2007, 24(8):1596-1599. 10.1093/molbev/msm092, 17488738.
59. Garr CD, Peterson JR, Schultz L, Oliver AR, Underiner TL, Cramer RD, Ferguson AM, Lawless MS, Patterson DE. Solution Phase Synthesis of Chemical Libraries for Lead Discovery. J Biomol Screen 1996, 1(4):179-186.